The initiation of a second phase 2 clinical trial with a novel drug candidate for the treatment of liver disease associated with Hepatitis C Virus (HCV) infection was announced.
CTS-1027 is an oral, small molecule compound that inhibits the activity of key members of a class of protease enzymes, the matrix metalloproteinases or MMPs. 

Link:http://www.pharmabiz.com/article/detnews.asp?articleid=50515
Source:Pharmabiz